David B. Finlay

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 3 papers. Top paper: “In vitro and in vivo pharmacological evaluation of the synthetic cannabinoid receptor agonist EG-018”.

In vitro and in vivo pharmacological evaluation of the synthetic cannabinoid receptor agonist EG-018

Pharmacology Biochemistry and Behavior(2020)10.1016/j.pbb.2020.172918

N/A

0DataRank · unranked

17 citations

Daniel G. Barrus, Richard C. Kevin, David B. Finlay, Timothy W. Lefever, Purvi R. Patel +6 more

Rational design of cannabinoid type-1 receptor allosteric modulators: Org27569 and PSNCBAM-1 hybrids

Bioorganic & Medicinal Chemistry(2021)10.1016/j.bmc.2021.116215

N/A

0DataRank · unranked

16 citations

Thomas F. Gamage, Ann M. Decker, David B. Finlay, Tiffany L. Langston, Daniel G. Barrus +4 more

The piperazine analogue para-fluorophenylpiperazine alters timing of the physiological effects of the synthetic cannabinoid receptor agonist AMB-FUBINACA, without changing its discriminative stimulus, signalling effects, or metabolism

Pharmacology Biochemistry and Behavior(2023)10.1016/j.pbb.2023.173530

N/A

0DataRank · unranked

2 citations

Warwick Mackie, Hunter D.J. Webb, Lucy R. Thomsen, Mhairi Nimick, Rhonda J. Rosengren +4 more